Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0	0	9.43	18.44	32.17	6.83
Revenue Growth (YoY)	-	-	-48.83%	-42.68%	371.02%	-
Gross Profit	0	0	9.43	18.44	32.17	6.83
Selling, General & Admin	51.8	46.54	32.81	21.97	12.94	10.8
Research & Development	172.25	167.51	105.77	75.46	50.52	38.85
Operating Expenses	224.04	214.05	138.58	97.43	63.47	49.65
Operating Income	-224.04	-214.05	-129.14	-78.99	-31.3	-42.82
Interest Expense / Income	0	0	0	0	0.48	1.43
Other Expense / Income	-35.28	-31.37	-3.89	-0.11	-2.69	-2.64
Pretax Income	-188.77	-182.69	-125.26	-78.89	-29.09	-41.62
Income Tax	-0.17	-0.29	0.12	-0.01	-0.26	-0.02
Net Income	-188.6	-182.39	-125.37	-78.88	-28.84	-41.6
Preferred Dividends	0	0	-0.44	-1.8	-0.82	-1.57
Net Income Common	-188.6	-182.39	-124.94	-77.09	-28.01	-40.03
Shares Outstanding (Basic)	78	67	61	44	35	26
Shares Outstanding (Diluted)	78	67	61	44	35	26
Shares Change	18.06%	10.48%	38.77%	26.30%	33.17%	33.53%
EPS (Basic)	-2.71	-2.73	-2.06	-1.77	-0.81	-1.54
EPS (Diluted)	-2.71	-2.73	-2.06	-1.77	-0.81	-1.54
Free Cash Flow	-157.69	-150.94	-101.32	-71.55	-50.76	-5.95
Free Cash Flow Per Share	-2.03	-2.26	-1.67	-1.64	-1.47	-0.23
Gross Margin	-	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-	-1368.91%	-428.45%	-97.31%	-627.02%
Profit Margin	-	-	-1324.32%	-418.11%	-87.09%	-586.13%
Free Cash Flow Margin	-	-	-1074.03%	-388.09%	-157.81%	-87.19%
EBITDA	-184.98	-179.14	-123.63	-77.98	-27.97	-39.76
EBITDA Margin	-	-	-1310.48%	-422.96%	-86.94%	-582.15%
Depreciation & Amortization	3.79	3.54	1.62	0.91	0.64	0.43
EBIT	-188.77	-182.69	-125.26	-78.89	-28.61	-40.18
EBIT Margin	-	-	-1327.70%	-427.88%	-88.94%	-588.43%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).